Genitourinary Radiology: Page 13

FDA clears Theragnostics kidney agent NephroScan

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has cleared for market the NephroScan technetium-99m (Tc-99m) radiodiagnostic imaging agent from radiopharmaceuticals firm Theragnostics.

February 22, 2022

MRI and PET match diagnosing prostate cancer

By Will Morton

MRI and PSMA-PET are equally effective diagnostic tools for detecting clinically significant tumors in patients with prostate cancer, according to a study published February 16 in the Journal of Medical Imaging and Radiation Oncology.

February 17, 2022

Shine and Telix ink Lu-177 supply deal

By AuntMinnie.com staff writers

Medical isotope company Shine Technologies and Telix Pharmaceuticals have signed an agreement covering the supply of lutetium-177 (Lu-177) to Telix for clinical development of potential new therapeutics to treat prostate and kidney cancer.

February 9, 2022

Ionetix, Precision Molecular ink supply deal

By AuntMinnie.com staff writers

Cyclotron technology developer Ionetix and imaging biomarker and theranostics firm Precision Molecular have signed a supply deal for the therapeutic isotope astatine-211.

January 27, 2022

3D printing enhances treatment of kidney stones

By Erik L. Ridley

The combination of percutaneous nephrolithotomy and 3D-printed models produced from patient CT scans enables significantly better treatment of complex renal calculi, or kidney stones, according to research published January 10 in Scientific Reports.

January 11, 2022

Telix secures FDA clearance for prostate cancer PET imaging agent

By AuntMinnie.com staff writers

Telix Pharmaceuticals has secured clearance from the U.S. Food and Drug Administration (FDA) for its Illuccix gallium-68 gozetotide prostate cancer PET imaging agent.

December 19, 2021

Deep learning of prostate MRI cancer measures up to radiologists

By Kate Madden Yee

A deep-learning algorithm performed comparably to radiologist interpretations when it came to identifying prostate cancer on multiparametric MRI, according to study results presented at the RSNA 2021 meeting.

December 15, 2021

When to biopsy: How prostate MRI can transform best practice

By Philip Ward

In the era of MRI targeting, do all prostate cancer patients require an additional 12-core systematic biopsy? Moving away from default systematic biopsy in some cases may be wise, according to German researcher Dr. Dominik Deniffel, who has won a prestigious award for trainees at RSNA 2021.

December 1, 2021

New radiotracer improves management of prostate cancer patients

By Will Morton

PET imaging with the radiotracer F-18 DCFPyL detects more metastatic tumors and can significantly improve treatment decisions compared with conventional imaging in patients with prostate cancer, according to research presented Wednesday at RSNA 2021 in Chicago.

December 1, 2021

United Imaging sponsors talk at RSNA 2021

By AuntMinnie.com staff writers

United Imaging is sponsoring a talk at RSNA 2021 titled "Rethinking How Radiology Can Work in Practice" that will be available in person and virtually.

November 28, 2021

Lantheus deploys prostate cancer software in U.S.

By AuntMinnie.com staff writers

Lantheus Holdings said its Pylarify AI prostate cancer software is now commercially available in the U.S.

November 28, 2021

Explainable artificial intelligence elevates prostate MRI reads

By Erik L. Ridley

Wednesday, December 1 | 8:00 a.m.-8:30 a.m. | SSGU05-4 | Room E353BAn explainable deep-learning software application can be highly accurate for characterizing prostate lesions on biparametric MRI exams, according to this scientific presentation.

November 23, 2021

Previous Page

Page 13 of 93

Next Page